Sugiyama E, Suzuki H, Tunru I S, Yamashita N, Hori T, Kobayashi M
First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.
J Rheumatol. 1994 Sep;21(9):1597-601.
To investigate the effect of a new immunosuppressant, FK506, on interleukin 6 (IL-6) production by freshly prepared rheumatoid synovial cells.
Rheumatoid synovial cells were isolated from synovial tissue of patients with rheumatoid arthritis (RA) by using collagenase and DNase treatment. The surface phenotypes of the cells were analyzed by 2-color fluorescent analysis with FACScan. The levels of IL-6 in supernatant of cultured synovial cells were measured by enzyme immunoassay.
The synovial cells used were mainly composed 32 +/- 1% of HLA-DR+/LeuM3+ cells and 53 +/- 6% of HLA-DR-/LeuM3-cells. These synovial cells spontaneously produced a large amount of IL-6 in culture. This spontaneous production of IL-6 was significantly inhibited by FK506 at the concentration of 10(-8) to 10(-6) M in a dose dependent manner. In the preincubation study, FK506 required more than 12 h to inhibit IL-6 production by synovial cells.
These results suggest that FK506 may be beneficial for patients with RA via inhibiting IL-6 production in inflammatory joints.
研究新型免疫抑制剂FK506对新鲜制备的类风湿滑膜细胞产生白细胞介素6（IL-6）的影响。
采用胶原酶和DNA酶处理，从类风湿关节炎（RA）患者的滑膜组织中分离出类风湿滑膜细胞。通过FACScan双色荧光分析对细胞的表面表型进行分析。采用酶免疫测定法测定培养的滑膜细胞上清液中IL-6的水平。
所用滑膜细胞主要由32±1%的HLA-DR+/LeuM3+细胞和53±6%的HLA-DR-/LeuM3-细胞组成。这些滑膜细胞在培养中自发产生大量IL-6。FK506在浓度为10（-8）至10（-6）M时以剂量依赖方式显著抑制IL-6的这种自发产生。在预孵育研究中，FK506需要超过12小时才能抑制滑膜细胞产生IL-6。
这些结果表明，FK506可能通过抑制炎症关节中IL-6的产生而对RA患者有益。
